A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Brock, Cathryn S
Gallo, James M
Price, Patricia M
Turkheimer, Federico E
Aboagye, E O
AffiliationClinical Sciences Centre, Imperial College, Faculty of Medicine, Hammersmith Hospital Campus, London, UK.
MetadataShow full item record
AbstractDifficulties in direct measurement of drug concentrations in human tissues have hampered the understanding of drug accumulation in tumors and normal tissues. We propose a new system analysis modeling approach to characterize drug distribution in tissues based on human positron emission tomography (PET) data. The PET system analysis method was applied to temozolomide, an important alkylating agent used in the treatment of brain tumors, as part of standard temozolomide treatment regimens in patients. The system analysis technique, embodied in the convolution integral, generated an impulse response function that, when convolved with temozolomide plasma concentration input functions, yielded predicted normal brain and brain tumor temozolomide concentration profiles for different temozolomide dosing regimens (75-200 mg/m(2)/d). Predicted peak concentrations of temozolomide ranged from 2.9 to 6.7 microg/mL in human glioma tumors and from 1.8 to 3.7 microg/mL in normal brain, with the total drug exposure, as indicated by the tissue/plasma area under the curve ratio, being about 1.3 in tumor compared with 0.9 in normal brain. The higher temozolomide exposures in brain tumor relative to normal brain were attributed to breakdown of the blood-brain barrier and possibly secondary to increased intratumoral angiogenesis. Overall, the method is considered a robust tool to analyze and predict tissue drug concentrations to help select the most rational dosing schedules.
CitationA new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. 2009, 69 (1):120-7 Cancer Res.
- Metabolic activation of temozolomide measured in vivo using positron emission tomography.
- Authors: Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar AS, Brock CS, Stevens MF, Newlands E, Jones T, Price P
- Issue date: 2003 May 15
- Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
- Authors: Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM
- Issue date: 2007 Jul 15
- Phase I trial of temozolomide using an extended continuous oral schedule.
- Authors: Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ
- Issue date: 1998 Oct 1
- Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
- Authors: Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R
- Issue date: 2004 Jun 1
- The effect of an adenosine A<sub>2A</sub> agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.
- Authors: Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA
- Issue date: 2018 Jan 15